Treatment of hyperlipidemia in primary practise in Germany: Sub-group analyses from the 4E-registry with particular emphasis on men and women with diabetes mellitus

被引:4
作者
Assmann, G.
Schulte, H.
Cullen, P. [1 ]
Neiss, A.
Bestehorn, K.
机构
[1] Univ Munster, Leibniz Inst Arteriosclerosis Res, D-48147 Munster, Germany
[2] Merck Sharp & Dohme GmbH, Haar, Germany
[3] Inst Med Stat & Epidemiol, Munich, Germany
关键词
cardiovascular incidences; cardiovascular risk management; coronary artery disease;
D O I
10.1055/s-2007-955094
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Aims: To investigate the achievement of treatment goals for low density lipoprotein (LDL) cholesterol in men and women with diabetes mellitus receiving statins in a primary-care setting in Germany. Methods: 6,827 men and 5,989 women with diabetes mellitus were recruited from among the 28,200 men and 24,200 women participating in the 4E registry of patients being treated with statins for primary hypercholesterolemia unresponsive to diet and lifestyle. Participants were assessed after 6 weeks and 9 months of statin therapy. Attainment of treatment targets was assessed (i) using individual LDL goals based on each participant's individual level of risk and (ii) based on the 2.6 mmol/L target recommended by current European and U.S. guidelines for persons with diabetes. Results: At baseline, patients with and without diabetes mellitus had similar LDL cholesterol levels patients (men: 4.5 +/- 1 vs. 4.7 +/- 1 mmol/L, women: 4.7 +/- 1 vs. 4.9 +/- 1 mmol/L respectively). The mean drop in LDL cholesterol on statin therapy was similar in men and women with and without diabetes, ranging from 26-27 percent all subgroups. After 9 months of statins, individual LDL goals were achieved by 25 % of men and 24 % of women with diabetes, while only 16% of diabetic men and 12% of diabetic women achieved the 2.6 mmol/L LDL target. These success rates were similar to those of non-diabetics, including those at high risk, in 4E. Conclusions: Patients with diabetes mellitus in 4E responded just as well to statins as patients without diabetes. However, achievement of treatment goals in patients with diabetes was just as poor as in other high-risk groups in the 4E cohort.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 30 条
[1]
ASSMAN G, 2006, IN PRESS EUROPEAN J
[2]
Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study [J].
Assmann, G ;
Cullen, P ;
Schulte, H .
CIRCULATION, 2002, 105 (03) :310-315
[3]
ASSMANN G, 2003, POCKET GUIDE PREVENT
[4]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[5]
WHY IS DIABETES-MELLITUS A STRONGER RISK FACTOR FOR FATAL ISCHEMIC-HEART-DISEASE IN WOMEN THAN IN MEN - THE RANCHO-BERNARDO STUDY [J].
BARRETTCONNOR, EL ;
COHN, BA ;
WINGARD, DL ;
EDELSTEIN, SL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (05) :627-631
[6]
Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease - 10-year follow-up of the Hoorn Study [J].
Becker, A ;
Bos, G ;
de Vegt, F ;
Kostense, PJ ;
Dekker, JM ;
Nijpels, G ;
Heine, RJ ;
Bouter, LM ;
Stehouwer, CDA .
EUROPEAN HEART JOURNAL, 2003, 24 (15) :1406-1413
[7]
The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men [J].
Cho, E ;
Rimm, EB ;
Stampfer, MJ ;
Willett, WC ;
Hu, FB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (05) :954-960
[8]
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[9]
Collins R, 2003, LANCET, V361, P2005
[10]
European guidelines on cardiovascular disease prevention in clinical practice -: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts) (vol 171, pg 145, 2003) [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, K ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
ATHEROSCLEROSIS, 2004, 173 (02) :379-391